

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 April 2025 (24.04.2025)



(10) International Publication Number
WO 2025/083628 A1

(51) International Patent Classification:

C07D 413/12 (2006.01) A61K 31/4245 (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2024/060259

(22) International Filing Date:

18 October 2024 (18.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202341071231 19 October 2023 (19.10.2023) IN

(71) Applicant: **AURIGENE ONCOLOGY LIMITED**
[IN/IN]; 39/40 (P), KIADB Industrial Area, Electronics
City Phase II, Karnataka, Bangalore 560100 (IN).

(72) Inventors: **SEETHARAMAIAH SETTY, Sudarshan**
Naremaddepalli; # 142, Pyramid Mahika, Jakkur Main
Road Shivanahalli, VTC: Jakkur, PO: Yelhanka, Bangalore
560064 (IN). **SASIKUMAR, Pottayil Govindan Nair**; #
5, Deccan Palms, Ananth Nagar Phase, II, Electronic city
post, Bangalore 560100 (IN). **ALLA, Manikantha Red-**
dy; H. No #9, 3rd Cross, B.t.r Gardens, Kudlu Main Road,
Madiwala Post, Bengaluru 560068 (IN). **CHAVAN, Rahul**
Baburao; Vinayaka Layout, Shantipura, Electronic City
Phase II, Bangalore 560100 (IN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PHARMACEUTICALLY ACCEPTABLE SALT OF A CD47-SIRP ALPHA PATHWAY INHIBITOR



(57) Abstract: The present disclosure relates to pharmaceutically acceptable salts of compound of formula (I), particularly alkali metal salts or alkaline earth metal salts, their crystalline forms and methods of their preparation. The disclosure also relates to preparations suitable for pharmaceutical uses for treatment of various diseases or disorders mediated by CD47, particularly cancer or other proliferative diseases.

WO 2025/083628 A1